Surrozen FY2030 Earnings Forecast Raised by HC Wainwright

Surrozen, Inc. (NASDAQ:SRZN) – Research analysts at HC Wainwright upped their FY2030 EPS estimates for shares of Surrozen in a note issued to investors on Friday, September 25th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($4.34) per share for the year, up from their previous forecast of ($5.53). HC Wainwright currently has a “Buy” rating and a $54.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($1.01) per share.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.88. The firm had revenue of $5.00 million during the quarter, compared to analyst estimates of $0.47 million.

Several other equities analysts have also weighed in on SRZN. William Blair assumed coverage on shares of Surrozen in a report on Thursday, August 20th. They set an “outperform” rating and a $51.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Friday, July 17th. Finally, Zacks Research upgraded shares of Surrozen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.33.

Surrozen Stock Performance

NASDAQ SRZN opened at $32.18 on Tuesday. The firm has a market capitalization of $373.61 million, a price-to-earnings ratio of -0.79 and a beta of 0.56. Surrozen has a one year low of $11.39 and a one year high of $37.83. The company’s 50 day moving average price is $22.43 and its 200 day moving average price is $24.99.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Perceptive Advisors LLC acquired a new position in Surrozen in the first quarter worth approximately $6,682,000. Empery Asset Management LP acquired a new stake in shares of Surrozen during the 4th quarter valued at $2,350,000. 5AM Venture Management LLC boosted its stake in shares of Surrozen by 25.0% during the 4th quarter. 5AM Venture Management LLC now owns 387,500 shares of the company’s stock worth $8,758,000 after acquiring an additional 77,500 shares in the last quarter. Spruce Street Capital LP acquired a new position in shares of Surrozen in the 4th quarter worth $9,764,000. Finally, Renaissance Technologies LLC raised its position in shares of Surrozen by 117.1% during the first quarter. Renaissance Technologies LLC now owns 49,126 shares of the company’s stock worth $1,431,000 after purchasing an additional 26,500 shares during the period. Institutional investors own 66.57% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the firm’s stock in a transaction on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total transaction of $6,906,250.00. Following the transaction, the insider directly owned 574,047 shares of the company’s stock, valued at approximately $12,198,498.75. This trade represents a 36.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 31.74% of the stock is currently owned by corporate insiders.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biotechnology company developing regenerative medicines designed to activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen’s approach is intended to stimulate the pathway selectively in specific tissues while limiting unwanted effects elsewhere in the body.

The company’s product candidates are based on engineered antibody therapeutics and its proprietary SWEETS platform. Surrozen has focused its research on potential treatments for diseases affecting the liver, gastrointestinal system and eyes, where impaired tissue repair or abnormal signaling may contribute to disease progression.